Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
20 participants
OBSERVATIONAL
2023-02-01
2024-04-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The EFFect of hIgh Dose ClopIdogrel treatmENT in Patients With Clopidogrel Resistance
NCT01032668
A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects
NCT00699998
Salts of Clopidogrel: Investigation to ENsure Clinical Equivalence
NCT02126982
Effects of Optimized Antiplatelet Treatment After Percutaneous Coronary Intervention
NCT00404781
Clopidogrel Efficacy and Acute Coronary Syndromes
NCT00839267
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
control
isotonic infusion
No interventions assigned to this group
nitrate
nitrate infusion
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients aged 18 to 75 years
* positive troponin levels,
* blood pressure above 120/70 mmHg
Exclusion Criteria
* ST elevation on electrocardiography, atrial fibrillation,
* recurrent angina,
* use of narcotic analgesics (e.g., morphine), nitrates and glycoprotein IIb/IIIa inhibitors during hospitalization,
* history of coronary artery bypass graft (CABG) surgery,
* active infection,
* uncontrolled hypertension,
* diabetes, cerebrovascular accident, Use P2Y12 inhibitor, proton pump inhibitor, oral anticoagulant, statin, CYP enzyme-inducing or inhibiting drugs at the time of admission,
* active systemic disease (e.g., malignancy, thyroid disorders chronic inflammatory diseases, liver dysfunction),
* left ventricular systolic dysfunction (ejection fraction \<50%),
* glomerular filtration rate \<60 mL/min/1.73m2,
* allergy to ASA or clopidogrel, coagulopathy,
* platelet counts below 100,000/μl and hematocrit levels below 29%, or exceeding 52%.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bursa Postgraduate Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hasan ARI
Professor Doctor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Bursa Yüksek İhtisas Hastanesi
Bursa, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Melek M, Ari H, Karakus A, Ari S, Tutuncu A, Bozat T. Impact of Intravenous Nitrate Treatment on Antiplatelet Effects of Clopidogrel in Acute Coronary Syndrome Patients: A Pilot Study. J Cardiovasc Pharmacol Ther. 2025 Jan-Dec;30:10742484251357147. doi: 10.1177/10742484251357147. Epub 2025 Jul 2.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Bursa Yüksek İhtisas
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.